MedPath

Can Hematological Inflammatory Indexes be Used to Differentiate Type 1 Modic Changes From Brucella Spondylodiscitis

Completed
Conditions
Brucella Spondylitis
Interventions
Other: C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.
Registration Number
NCT06432530
Lead Sponsor
Yuzuncu Yıl University
Brief Summary

Hematological inflammatory indices (Table 2) are currently very popular and have diagnostic, prognostic, and predictive, roles in various diseases. Considering their promising roles, we hypothesized that hematological inflammatory indices may have a distinctive value between brucella spondylodiscitis and type 1 Modic Changes (MCs). If the hypothesis is valid, early diagnosis-differential diagnosis-treatment processes may become easier and more successful. Given that hematological inflammatory indices are faster, practical, simpler, inexpensive, and easily accessible indicators, they may be more appropriate tools in differentiation between brucella spondylodiscitis and type 1 MCs.

Detailed Description

This is a retrospective comparative study focusing to distinguish between brucella spondylodiscitis and type 1 MCs considering hematological inflammatory indexes. Patients' data were obtained from Hospital Information Systems, between 2020 to 2024. A total of 35 patients with brucella spondylodiscitis and 37 type 1 MCs were enrolled in the study. Diagnoses of brucella spondylodiscitis and type 1 MCs were supported by microbiological, serological, and radiological diagnostic tools. Patients' hematological parameters were recorded, and hematological inflammatory indexes (NLR, MLR, PLR, NLPR, SII, SIRI, AISI) were derived from baseline CBC tests.

Based on the diagnostic tools and criteria1,2,14,21, cases diagnosed with lumbar brucella spondylodiscitis or lumbar type 1 MCs in the past 5 years and who had simultaneously lumbar MRI, Complete Blood Count (CBC) test, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) results, and aged 18-65 years were selected to yield a study population. On the other hand, cases with inadequate data, aged \<18 or \>64 years, other infectious spondylodiscitis types than brucella, other MCs types than type 1, and other non-infectious conditions such as rheumatic spondylodiscitis (ankylosing spondylitis or Andersson lesion) were excluded from the study. Also, previous or recurrent brucella spondylodiscitis, involved other spinal levels than the lumbar spine were exclusion causes.

The two groups were statistically assessed and compared for baseline features such as age, gender, symptom duration, CRP, ESR, CBC values, and indexes derived from the CBC.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
72
Inclusion Criteria
  • Clinical diagnosis of lumbar brucella spondylodiscitis in the past 5 years
  • Clinical diagnosis of or lumbar type 1 Modic Changes (MCs) in the past 5 years
  • Having simultaneously lumbar Magnetic Resonance Imaging (MRI), Complete Blood Count (CBC) test, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) results
  • Being between the ages of 18-65
Exclusion Criteria
  • Cases with inadequate data
  • Being under 18 years of age and over 65 years of age
  • Having other infectious spondylodiscitis types than brucella
  • Having other MCs types than type 1
  • Having other non-infectious conditions such as rheumatic spondylodiscitis (ankylosing spondylitis or Andersson lesion)
  • Having previous or recurrent brucella spondylodiscitis, involved other spinal levels than the lumbar spine

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
35 patients with brucella spondylodiscitisC-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.Diagnoses of brucella spondylodiscitis and type 1 MCs were supported by microbiological, serological, and radiological diagnostic tools. Based on the diagnostic tools and criteria, cases diagnosed with lumbar brucella spondylodiscitis or lumbar type 1 MCs in the past 5 years and who had simultaneously lumbar Magnetic Resonance Imaging (MRI), Complete Blood Count (CBC) test, C-reactive protein (CRP), and Erythrocyte Sedimentation Rate (ESR) results, and aged 18-65 years were selected to yield a study population
37 patients with type 1 Modic Changes (MCs)C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.Diagnoses of brucella spondylodiscitis and type 1 MCs were supported by microbiological, serological, and radiological diagnostic tools. Based on the diagnostic tools and criteria, cases diagnosed with lumbar brucella spondylodiscitis or lumbar type 1 MCs in the past 5 years and who had simultaneously lumbar Magnetic Resonance Imaging (MRI), Complete Blood Count (CBC) test, C-reactive protein (CRP), and Erythrocyte Sedimentation Rate (ESR) results, and aged 18-65 years were selected to yield a study population
Primary Outcome Measures
NameTimeMethod
Neutrophil/Lymphocyte Rate (NLR)Baseline

As a hematological inflammatory index

(neutrophil*platelet/lymphocyte): Systemic Inflammatory Index (SII)Baseline

As a hematological inflammatory index

Erythrocyte Sedimentation Rate (ESR)Baseline

As an inflammatory index.

(neutrophil*monocyte/lymphocyte): Systemic Inflammatory Response Index (SIRI)Baseline

As a hematological inflammatory index

(neutrophil*platelet*monocyte/lymphocyte): Aggregate Index of Systemic Inflammation (AISI)Baseline

As a hematological inflammatory index

Platelet/Lymphocyte Rate (PLR)Baseline

As a hematological inflammatory index

C-Reactive Protein (CRP)Baseline

As an inflammatory index.

Monocyte/Lymphocyte Rate (MLR)Baseline

As a hematological inflammatory index

Neutrophil/(Lymphocyte*Platelet) Rate (NLPR)Baseline

As a hematological inflammatory index

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Volkan Şah

🇹🇷

Van, Turkey

© Copyright 2025. All Rights Reserved by MedPath